Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 8, 2008, Pages 497-505

  Samaha, Frederick F ^a,b   McKenney, James ^c   Bloedon, LeAnne T ^a   Sasiela, William J ^d   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Aegerion Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEGR 733; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; INFECTION; INJURY; KIDNEY DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THERMAL INJURY; TREATMENT DURATION; VASCULAR DISEASE; WEIGHT CHANGE;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BENZIMIDAZOLES; CARRIER PROTEINS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MICROSOMES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 48349088178     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1250     Document Type: Article

References (28)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497
2. Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110: 227-239
3. Smith SC Jr et al. (2006) AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular DiseaseE 2006 Update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372
4. Ballantyne CM et al. (2005) Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 149: 464-473
5. Baigent C et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278
6. Andrews T et al. (2001) Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five Statins. Am J Med 111: 185-191
7. Alsheikh-Ali AA and Karas RH (2005) Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 8: 95-97
8. Ballantyne CM et al. (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163: 553-564
9. Burnett JR and Watts GF (2007) MTP inhibition as a treatment for dyslipidaemias: Time to deliver or empty promises? Expert Opin Ther Targets 11: 181-189
10. Sharp D et al. (1993) Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365: 65-69
11. Rader DJ and Brewer HB (1993) Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 270: 865-869
12. Liao W et al. (2003) Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 44: 978-985
13. Wetterau JR et al. (1998) An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282: 751-754
14. Cuchel M et al. (2007) Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356: 148-156
15. Svedlund J et al. (1988) GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33: 129-134
16. Revicki DA et al. (1998) Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1: 75-83
17. Kulich KR et al. (2003) Psychometric validation of the German translation of the Gastrointestinal rating scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QUOLRAD) Questionnaire in patients with reflux disease. Health Qual Life Outcomes 7: 62
18. Davidson MH and Robinson JG (2006) Lipid-lowering effects of statins: A comparative review. Expert Opin Pharmacother 7: 1701-1714
19. Knopp RH et al. (2003) Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24: 729-741
20. Chandler CE et al. (2003) CP-346086: An MTP inhibitor that lowers plasma total, VLDL, and LDL cholesterol and triglycerides by up to 70% in experimental animals and in humans. J Lipid Res 44: 1887-1901
21. Stern L et al. (2004) The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Ann Intern Med 140: 778-785
22. Ornish D et al. (1998) Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280: 2001-2007
23. Ikewaki K et al. (1994) In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res 35: 1809-1819
24. Guerciolini R et al. (2001) comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obesity Res 9: 364-367
25. Temel RE et al. (2007) Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117: 1968-1978.
26. Sorbera LA et al. (2000) Implitapide. Drugs Fut 25: 1138-1144 [doi:20002511]
27. Zaiss S et al. (1999) BAY 13-9952, an inhibitor of the microsomal triglyceride transfer protein (MTP), inhibits atherosclerotic plaque formation in cholesterol-fed rabbits in spite of a concomitant reductio of vitamin E [Abstr]. Circulation. 100 (Suppl 1): 258
28. Zaiss S and Sander E (2000) Bay 13-9952 (implitapide), an inhibitor of the microsomal triglyceride transfer protein (MTP), inhibits atherosclerosis and prolongs lifetime in apoE knockout mice. Eur Heart J 21 (Suppl): 16